Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy

Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures

(2015) Xue Song et al.   BMC HEALTH SERVICES RESEARCH

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

(2015) Xin-Lin Zhang et al.   BMC Medicine

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

(2015) Michael J. Lipinski et al.   EUROPEAN HEART JOURNAL

New Therapies in the Treatment of High Cholesterol

(2015) William H. Shrank et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs

(2015) Brendan M. Everett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future

(2015) Evan A. Stein et al.   Current Cardiology Reports

Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults — United States, 2005–2012

(2015) Carla Mercado et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States

(2013) Stanley H. Hsia et al.   Journal of Clinical Lipidology

Non–High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults

(2013) Mohamed B. Elshazly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Promoting Health and Wellness in the Workplace: A Unique Opportunity to Establish Primary and Extended Secondary Cardiovascular Risk Reduction Programs

(2013) Ross Arena et al.   MAYO CLINIC PROCEEDINGS

Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006

(2012) Peter P. Tóth et al.   Journal of Clinical Lipidology

Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials

(2011) George A Kelley et al.   BMC Medicine

Value of Primordial and Primary Prevention for Cardiovascular Disease

(2011) William S. Weintraub et al.   CIRCULATION

Forecasting the Future of Cardiovascular Disease in the United States

(2011) Paul A. Heidenreich et al.   CIRCULATION

Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance

(2011) Charles J. Glueck et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

(2010) Robert L. Ohsfeldt et al.   JOURNAL OF MEDICAL ECONOMICS

Impact of Worksite Wellness Intervention on Cardiac Risk Factors and One-Year Health Care Costs

(2009) Richard V. Milani et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lipid Treatment Assessment Project 2

(2009) David D. Waters et al.   CIRCULATION

Comparison of Low-Fat Versus Mediterranean-Style Dietary Intervention After First Myocardial Infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial)††Conflicts of interest: Dr. Bibus has received consulting fees from companies that make fish oil, Coromega Co., Vista, CA, and Enreco, Inc., Newton, WI. He also has equity ownership in Lipid Technologies, LLC, Austin, MN, the company that performed the plasma fatty acid analysis. Dr. Bibus owns patents related to lipid therapy. He has served as an expert witness regarding lipids and fatty acids.

(2008) Katherine R. Tuttle et al.   AMERICAN JOURNAL OF CARDIOLOGY

Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

(2008) Devin Mann et al.   ANNALS OF PHARMACOTHERAPY